{
  "run": {
    "id": "cmnr15j8j06z0p6583e2i5sxq",
    "region": "US",
    "assetId": "cmnr15j7o06ywp658hhumnwv9",
    "ticker": "WAT",
    "snapshotId": "cmnr15j8306yyp6582x0ijmtd",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:22:08.416Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr15j8306yyp6582x0ijmtd",
      "assetId": "cmnr15j7o06ywp658hhumnwv9",
      "asOf": "2026-04-08T20:00:00.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:00.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:00.000Z",
          "open": 315.425,
          "price": 318.53,
          "dayLow": 311.62,
          "volume": 1006213,
          "dayHigh": 322.98,
          "currency": "USD",
          "prevClose": 307.38,
          "week52Low": 275.05,
          "week52High": 414.15
        },
        "fundamentals": {
          "pe": 35.1694444444444,
          "beta": 0.967138093230684,
          "epsTTM": 10.8,
          "fcfTTM": 543616000,
          "growth": {
            "epsYoy": 0.00465116279069774,
            "revenueYoy": 0.06993642143505904
          },
          "sector": "Laboratory Analytical Instruments",
          "margins": {
            "net": 0.2389611599821082,
            "gross": 0.58927426569256,
            "operating": 0.2825611301625168
          },
          "website": null,
          "industry": null,
          "pegRatio": 75.614305555554,
          "ebitdaTTM": 1074506000,
          "forwardPe": 26.3770833333333,
          "marketCap": 20973515517,
          "totalCash": 587831000,
          "totalDebt": 1870000000,
          "debtEquity": 0.730114530372374,
          "quickRatio": 1.142941623994856,
          "revenueTTM": 536560000,
          "companyName": "WATERS CORP /DE/",
          "priceToBook": 8.82513384912476,
          "currentRatio": 1.732671829505308,
          "dividendYield": null,
          "returnOnAssets": 0.02525671962257833,
          "returnOnEquity": 0.250905224886988,
          "analystOpinions": null,
          "businessSummary": null,
          "enterpriseValue": 23885472470,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": null,
          "sharesOutstanding": 98101871,
          "enterpriseToEbitda": 22.22925927821715,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 44.51593944759207,
          "operatingCashflowTTM": 652555000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:22:08.403Z"
    },
    "results": [
      {
        "id": "cmnr15j8l06z2p658byunqko3",
        "runId": "cmnr15j8j06z0p6583e2i5sxq",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"AI Equity Research Model v1.0\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"WAT\",\"currency\":\"USD\",\"current_price\":318.53,\"target_price_6m\":325,\"target_price_12m\":332,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Premium analytical instruments franchise with strong recurring revenue base\",\"Valuation stretched at 35x TTM PE with near-zero EPS growth\",\"Forward PE of 26x implies meaningful earnings acceleration ahead\",\"Strong FCF generation (~$544M TTM) supports capital returns and debt reduction\",\"Macro and pharma end-market uncertainty caps near-term upside potential\"],\"key_drivers\":[{\"driver\":\"Pharma/biotech end-market instrument demand recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"China market normalization and stimulus-driven spending\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Recurring revenue from consumables and service (~60% of mix)\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated PEG ratio (75.6x) signals growth-valuation disconnect\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Operating margin expansion potential toward 30%+\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Rising interest rates increasing WACC / discount rate pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Net debt of ~$1.3B manageable at <1.3x EBITDA\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Competitive pressure from Agilent and Thermo Fisher\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Prolonged pharma capex downturn compresses instrument orders\",\"China regulatory/geopolitical disruption reduces growth outlook\",\"FX headwinds from strong USD erode international revenue\",\"Multiple compression if EPS growth fails to accelerate from ~0.5% YoY\",\"Debt refinancing risk if rates stay elevated longer\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.30,\"wacc\":0.095,\"terminal_multiple\":24},\"scenarios\":{\"bear\":{\"target_price\":270,\"prob\":0.20,\"notes\":\"Pharma capex remains weak, China sluggish, multiple compresses to ~22x forward PE.\"},\"base\":{\"target_price\":332,\"prob\":0.55,\"notes\":\"Mid-single-digit revenue growth, modest margin expansion, stable ~26x forward PE.\"},\"bull\":{\"target_price\":385,\"prob\":0.25,\"notes\":\"Strong instrument cycle recovery, China rebound, EPS acceleration re-rates to ~30x forward PE.\"}},\"method_notes\":\"Valuation anchored on forward PE (26.4x snapshot) with normalized EPS growth of 10-12% implied by forward vs TTM gap. Base 12M target = ~$12.75 est. forward EPS × 26x. Revenue TTM ($537M) appears inconsistent with EBITDA/FCF/EPS figures—likely a quarterly figure; used EPS/multiples as primary anchor. Expected 12M return ~4.2% supports HOLD per rubric. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "AI Equity Research Model v1.0",
          "risks": [
            "Prolonged pharma capex downturn compresses instrument orders",
            "China regulatory/geopolitical disruption reduces growth outlook",
            "FX headwinds from strong USD erode international revenue",
            "Multiple compression if EPS growth fails to accelerate from ~0.5% YoY",
            "Debt refinancing risk if rates stay elevated longer"
          ],
          "ticker": "WAT",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Mid-single-digit revenue growth, modest margin expansion, stable ~26x forward PE.",
              "target_price": 332
            },
            "bear": {
              "prob": 0.2,
              "notes": "Pharma capex remains weak, China sluggish, multiple compresses to ~22x forward PE.",
              "target_price": 270
            },
            "bull": {
              "prob": 0.25,
              "notes": "Strong instrument cycle recovery, China rebound, EPS acceleration re-rates to ~30x forward PE.",
              "target_price": 385
            }
          },
          "confidence": 0.58,
          "assumptions": {
            "wacc": 0.095,
            "revenue_cagr_3y": 0.06,
            "terminal_multiple": 24,
            "ebit_margin_target": 0.3
          },
          "key_drivers": [
            {
              "driver": "Pharma/biotech end-market instrument demand recovery",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "China market normalization and stimulus-driven spending",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Recurring revenue from consumables and service (~60% of mix)",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Elevated PEG ratio (75.6x) signals growth-valuation disconnect",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Operating margin expansion potential toward 30%+",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Rising interest rates increasing WACC / discount rate pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Net debt of ~$1.3B manageable at <1.3x EBITDA",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Competitive pressure from Agilent and Thermo Fisher",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation anchored on forward PE (26.4x snapshot) with normalized EPS growth of 10-12% implied by forward vs TTM gap. Base 12M target = ~$12.75 est. forward EPS × 26x. Revenue TTM ($537M) appears inconsistent with EBITDA/FCF/EPS figures—likely a quarterly figure; used EPS/multiples as primary anchor. Expected 12M return ~4.2% supports HOLD per rubric. Not investment advice.",
          "current_price": 318.53,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Premium analytical instruments franchise with strong recurring revenue base",
            "Valuation stretched at 35x TTM PE with near-zero EPS growth",
            "Forward PE of 26x implies meaningful earnings acceleration ahead",
            "Strong FCF generation (~$544M TTM) supports capital returns and debt reduction",
            "Macro and pharma end-market uncertainty caps near-term upside potential"
          ],
          "target_price_6m": 325,
          "target_price_12m": 332
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 44021,
        "createdAt": "2026-04-09T05:22:08.416Z",
        "usage": {
          "inputTokens": 3497,
          "outputTokens": 1994,
          "costUsd": 0.067335
        }
      },
      {
        "id": "cmnr15j8l06z5p6589bh70pke",
        "runId": "cmnr15j8j06z0p6583e2i5sxq",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"equity_research_analyst\",\n  \"as_of\": \"2026-04-08T20:00:00.000Z\",\n  \"ticker\": \"WAT\",\n  \"currency\": \"USD\",\n  \"current_price\": 318.53,\n  \"target_price_6m\": 310,\n  \"target_price_12m\": 330,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\n    \"Stable mid-single-digit revenue growth.\",\n    \"High operating and net margins.\",\n    \"Strong cash flow generation supports investments.\",\n    \"Elevated valuation multiples pose risk.\",\n    \"Mixed earnings growth near-term.\"\n  ],\n  \"key_drivers\": [\n    { \"driver\": \"Revenue growth from life sciences demand\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"High PE multiple compression risk\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Strong free cash flow yield\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Economic sensitivity in capital spending\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n    { \"driver\": \"Innovation and new product pipeline\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Debt levels and interest expense\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n    { \"driver\": \"International expansion opportunities\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Competition from other instrument makers\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n  ],\n  \"risks\": [\"Valuation multiple decline\", \"Slower EPS growth than expected\", \"Regulatory headwinds\", \"Macroeconomic downturn\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.07,\n    \"ebit_margin_target\": 0.285,\n    \"wacc\": 0.09,\n    \"terminal_multiple\": 20\n  },\n  \"scenarios\": {\n    \"bear\": { \"target_price\": 300, \"prob\": 0.2, \"notes\": \"Multiple compression and growth slowdown.\" },\n    \"base\": { \"target_price\": 330, \"prob\": 0.6, \"notes\": \"Steady growth and stable multiples.\" },\n    \"bull\": { \"target_price\": 360, \"prob\": 0.2, \"notes\": \"Accelerated growth and multiple expansion.\" }\n  },\n  \"method_notes\": \"Valuation based on DCF with assumed growth and margins; HOLD as upside limited by high current valuation. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "equity_research_analyst",
          "risks": [
            "Valuation multiple decline",
            "Slower EPS growth than expected",
            "Regulatory headwinds",
            "Macroeconomic downturn"
          ],
          "ticker": "WAT",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady growth and stable multiples.",
              "target_price": 330
            },
            "bear": {
              "prob": 0.2,
              "notes": "Multiple compression and growth slowdown.",
              "target_price": 300
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated growth and multiple expansion.",
              "target_price": 360
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.07,
            "terminal_multiple": 20,
            "ebit_margin_target": 0.285
          },
          "key_drivers": [
            {
              "driver": "Revenue growth from life sciences demand",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "High PE multiple compression risk",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Strong free cash flow yield",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Economic sensitivity in capital spending",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Innovation and new product pipeline",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Debt levels and interest expense",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "International expansion opportunities",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competition from other instrument makers",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on DCF with assumed growth and margins; HOLD as upside limited by high current valuation. Not investment advice.",
          "current_price": 318.53,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Stable mid-single-digit revenue growth.",
            "High operating and net margins.",
            "Strong cash flow generation supports investments.",
            "Elevated valuation multiples pose risk.",
            "Mixed earnings growth near-term."
          ],
          "target_price_6m": 310,
          "target_price_12m": 330
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 345,
        "createdAt": "2026-04-09T05:22:08.416Z",
        "usage": {
          "inputTokens": 2020,
          "outputTokens": 4899,
          "costUsd": 0.002623
        }
      },
      {
        "id": "cmnr15j8l06z3p6581fviuu8k",
        "runId": "cmnr15j8j06z0p6583e2i5sxq",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"EquityResearch_Base_v1\",\n  \"as_of\": \"2026-04-08T20:00:00.000Z\",\n  \"ticker\": \"WAT\",\n  \"currency\": \"USD\",\n  \"current_price\": 318.53,\n  \"target_price_6m\": 310.00,\n  \"target_price_12m\": 330.00,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"High-quality franchise with strong recurring revenue from consumables and services.\",\n    \"Near-term biopharma capex constraints limit instrument sales growth and visibility.\",\n    \"Premium valuation at 35x trailing P/E leaves little room for execution missteps.\",\n    \"Solid free cash flow generation supports share repurchases and debt reduction.\",\n    \"Long-term secular tailwinds in life sciences remain intact despite cyclical pause.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Biopharma capital expenditure trends\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"China market recovery\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Consumables and service attachment rates\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Foreign exchange fluctuations\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"New product cycles and adoption\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Academic and government funding\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Prolonged weakness in global biopharma spending and instrument replacement cycles.\",\n    \"Slower-than-expected recovery in the Chinese end-market.\",\n    \"Increased competition in liquid chromatography and mass spectrometry.\",\n    \"Margin compression from inflation or supply chain costs.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.055,\n    \"ebit_margin_target\": 0.29,\n    \"wacc\": 0.082,\n    \"terminal_multiple\": 22.0\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 260.00,\n      \"prob\": 0.25,\n      \"notes\": \"Prolonged biopharma capex freeze and China weakness compress multiples to 20x forward earnings.\"\n    },\n    \"base\": {\n      \"target_price\": 330.00,\n      \"prob\": 0.55,\n      \"notes\": \"Gradual recovery in instrument sales with steady consumables growth; valuation remains near historical averages.\"\n    },\n    \"bull\": {\n      \"target_price\": 380.00,\n      \"prob\": 0.20,\n      \"notes\": \"Rapid rebound in pharma spending and successful new product launches drive multiple expansion to 30x.\"\n    }\n  },\n  \"method_notes\": \"Valuation based on a blend of DCF (8.2% WACC, 2.5% TGR) and forward P/E (27x applied to NTM EPS). The HOLD rating reflects a balanced risk/reward profile given the premium valuation and near-term cyclical headwinds in biopharma end-markets. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "EquityResearch_Base_v1",
          "risks": [
            "Prolonged weakness in global biopharma spending and instrument replacement cycles.",
            "Slower-than-expected recovery in the Chinese end-market.",
            "Increased competition in liquid chromatography and mass spectrometry.",
            "Margin compression from inflation or supply chain costs."
          ],
          "ticker": "WAT",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Gradual recovery in instrument sales with steady consumables growth; valuation remains near historical averages.",
              "target_price": 330
            },
            "bear": {
              "prob": 0.25,
              "notes": "Prolonged biopharma capex freeze and China weakness compress multiples to 20x forward earnings.",
              "target_price": 260
            },
            "bull": {
              "prob": 0.2,
              "notes": "Rapid rebound in pharma spending and successful new product launches drive multiple expansion to 30x.",
              "target_price": 380
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.082,
            "revenue_cagr_3y": 0.055,
            "terminal_multiple": 22,
            "ebit_margin_target": 0.29
          },
          "key_drivers": [
            {
              "driver": "Biopharma capital expenditure trends",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "China market recovery",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Consumables and service attachment rates",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Foreign exchange fluctuations",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "New product cycles and adoption",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Academic and government funding",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation based on a blend of DCF (8.2% WACC, 2.5% TGR) and forward P/E (27x applied to NTM EPS). The HOLD rating reflects a balanced risk/reward profile given the premium valuation and near-term cyclical headwinds in biopharma end-markets. Not investment advice.",
          "current_price": 318.53,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "High-quality franchise with strong recurring revenue from consumables and services.",
            "Near-term biopharma capex constraints limit instrument sales growth and visibility.",
            "Premium valuation at 35x trailing P/E leaves little room for execution missteps.",
            "Solid free cash flow generation supports share repurchases and debt reduction.",
            "Long-term secular tailwinds in life sciences remain intact despite cyclical pause."
          ],
          "target_price_6m": 310,
          "target_price_12m": 330
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-pro-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 24534,
        "createdAt": "2026-04-09T05:22:08.416Z",
        "usage": {
          "inputTokens": 2366,
          "outputTokens": 863,
          "costUsd": 0.015088
        }
      },
      {
        "id": "cmnr15j8l06z1p658jiueoo3x",
        "runId": "cmnr15j8j06z0p6583e2i5sxq",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:00.000Z\",\"ticker\":\"WAT\",\"currency\":\"USD\",\"current_price\":318.53,\"target_price_6m\":329,\"target_price_12m\":335,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Recurring service and consumables support resilient cash generation.\",\"Pharma and QA demand should sustain mid-single-digit organic growth.\",\"Margins remain best-in-class, but expansion room looks limited.\",\"Valuation already discounts a quality premium versus growth.\",\"Recent setup favors steady compounding more than outsized rerating.\"],\"key_drivers\":[{\"driver\":\"Biopharma end-market recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Industrial QA and PFAS testing\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Service and consumables mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"New product cycle adoption\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"China demand normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Operating margin discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX and academic funding\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"China and academic demand stay weak.\",\"Large pharma capex remains cautious.\",\"Multiple compression outweighs earnings growth.\",\"Execution missteps on launches or M&A.\"],\"assumptions\":{\"revenue_cagr_3y\":0.065,\"ebit_margin_target\":0.295,\"wacc\":0.082,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":295,\"prob\":0.25,\"notes\":\"Growth slows and premium multiple compresses.\"},\"base\":{\"target_price\":335,\"prob\":0.5,\"notes\":\"Steady mid-single-digit growth with stable margins.\"},\"bull\":{\"target_price\":380,\"prob\":0.25,\"notes\":\"China improves and new products drive faster mix-led growth.\"}},\"method_notes\":\"Blended quality-compounder valuation using snapshot quote, margins, FCF and a conservative forward EV/EBIT anchor. Snapshot revenueTTM appears inconsistent with EV/EBITDA, so I relied more on PE/cash-flow context and margin quality. 12M upside is ~5%, consistent with HOLD. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "gpt-5",
          "risks": [
            "China and academic demand stay weak.",
            "Large pharma capex remains cautious.",
            "Multiple compression outweighs earnings growth.",
            "Execution missteps on launches or M&A."
          ],
          "ticker": "WAT",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady mid-single-digit growth with stable margins.",
              "target_price": 335
            },
            "bear": {
              "prob": 0.25,
              "notes": "Growth slows and premium multiple compresses.",
              "target_price": 295
            },
            "bull": {
              "prob": 0.25,
              "notes": "China improves and new products drive faster mix-led growth.",
              "target_price": 380
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 0.082,
            "revenue_cagr_3y": 0.065,
            "terminal_multiple": 22,
            "ebit_margin_target": 0.295
          },
          "key_drivers": [
            {
              "driver": "Biopharma end-market recovery",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Industrial QA and PFAS testing",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Service and consumables mix",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "New product cycle adoption",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "China demand normalization",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Premium valuation multiple",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Operating margin discipline",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "FX and academic funding",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended quality-compounder valuation using snapshot quote, margins, FCF and a conservative forward EV/EBIT anchor. Snapshot revenueTTM appears inconsistent with EV/EBITDA, so I relied more on PE/cash-flow context and margin quality. 12M upside is ~5%, consistent with HOLD. not investment advice",
          "current_price": 318.53,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Recurring service and consumables support resilient cash generation.",
            "Pharma and QA demand should sustain mid-single-digit organic growth.",
            "Margins remain best-in-class, but expansion room looks limited.",
            "Valuation already discounts a quality premium versus growth.",
            "Recent setup favors steady compounding more than outsized rerating."
          ],
          "target_price_6m": 329,
          "target_price_12m": 335
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0f3a414afe34c8460069d75eb0ee108195836ef55228433f50",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 40604,
        "createdAt": "2026-04-09T05:22:08.416Z",
        "usage": {
          "inputTokens": 2291,
          "outputTokens": 2375,
          "costUsd": 0.037259
        }
      },
      {
        "id": "cmnr15j8l06z4p6587o9x59ya",
        "runId": "cmnr15j8j06z0p6583e2i5sxq",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:00.000Z\",\n  \"ticker\": \"WAT\",\n  \"currency\": \"USD\",\n  \"current_price\": 318.53,\n  \"target_price_6m\": 325,\n  \"target_price_12m\": 335,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Waters maintains leadership in HPLC and mass spec instruments.\",\n    \"Recurring revenue from consumables provides earnings stability.\",\n    \"Elevated 35x P/E ratio limits near-term upside potential.\",\n    \"Low single-digit growth persists amid soft end markets.\",\n    \"Innovation in LC-MS portfolio offers long-term opportunities.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Biopharma R&D budgets\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"LC-MS product adoption\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"China market recovery\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competition from Agilent/Thermo\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Operating margin expansion\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Macro lab spending cuts\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"FX and tariff impacts\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Prolonged biopharma funding weakness\",\n    \"Intensifying competitive pressure\",\n    \"Supply chain and cost inflation\",\n    \"Execution risk on product launches\",\n    \"Adverse FX and trade policies\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.06,\n    \"ebit_margin_target\": 0.29,\n    \"wacc\": 0.085,\n    \"terminal_multiple\": 24\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 255,\n      \"prob\": 0.35,\n      \"notes\": \"Extended demand weakness and margin erosion.\"\n    },\n    \"base\": {\n      \"target_price\": 335,\n      \"prob\": 0.45,\n      \"notes\": \"Stable low-single-digit growth at current multiples.\"\n    },\n    \"bull\": {\n      \"target_price\": 410,\n      \"prob\": 0.2,\n      \"notes\": \"Strong product cycle and market share gains.\"\n    }\n  },\n  \"method_notes\": \"DCF using assumed 6% revenue CAGR, 29% EBIT margin, 8.5% WACC and 24x terminal EV/EBITDA. High valuation offsets modest growth; mixed evidence supports HOLD. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:00.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Prolonged biopharma funding weakness",
            "Intensifying competitive pressure",
            "Supply chain and cost inflation",
            "Execution risk on product launches",
            "Adverse FX and trade policies"
          ],
          "ticker": "WAT",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.45,
              "notes": "Stable low-single-digit growth at current multiples.",
              "target_price": 335
            },
            "bear": {
              "prob": 0.35,
              "notes": "Extended demand weakness and margin erosion.",
              "target_price": 255
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong product cycle and market share gains.",
              "target_price": 410
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.06,
            "terminal_multiple": 24,
            "ebit_margin_target": 0.29
          },
          "key_drivers": [
            {
              "driver": "Biopharma R&D budgets",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "LC-MS product adoption",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "China market recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competition from Agilent/Thermo",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Operating margin expansion",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Macro lab spending cuts",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "FX and tariff impacts",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using assumed 6% revenue CAGR, 29% EBIT margin, 8.5% WACC and 24x terminal EV/EBITDA. High valuation offsets modest growth; mixed evidence supports HOLD. Not investment advice.",
          "current_price": 318.53,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Waters maintains leadership in HPLC and mass spec instruments.",
            "Recurring revenue from consumables provides earnings stability.",
            "Elevated 35x P/E ratio limits near-term upside potential.",
            "Low single-digit growth persists amid soft end markets.",
            "Innovation in LC-MS portfolio offers long-term opportunities."
          ],
          "target_price_6m": 325,
          "target_price_12m": 335
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "c75d9eb6-c82c-92d4-ab12-921659841da9",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 16275,
        "createdAt": "2026-04-09T05:22:08.416Z",
        "usage": {
          "inputTokens": 2629,
          "outputTokens": 3005,
          "costUsd": 0.052962
        }
      }
    ]
  }
}